Savara (SVRA) AI Stock Analysis

• Market Cap: $1.02B
• Dividend Yield: N/A
• Average Volume (3M): 1.80M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: N/A
• EPS Growth: -22.39%
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 204,657,500
• 10 Day Avg. Volume: 2,429,719
• 30 Day Avg. Volume: 1,802,342
• PEG Ratio: -1.08
• Price to Book (P/B): 6.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.27
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -760.77
• Enterprise Value/Ebitda: -8.30
• 1Y Price Target: $10.25
• Price Target Upside: 106.65% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.42
• Revenue Forecast (FY): $16.54M

• Rating: 46 Neutral
• Price Target: $5.00 ▲(0.81% Upside)
• Action: Reiterated Date: 03/14/26
• Date: Action: Reiterated 03/14/26

The score is primarily held down by the financial profile—no revenue, accelerating losses, and high, worsening cash burn—alongside weak technical momentum. A comparatively solid equity base with manageable debt and mildly positive corporate updates provide limited offset, while valuation signals are constrained by negative earnings.

Positive Factors

Balance Sheet Strength

A meaningful increase in stockholders’ equity to ~$203M, combined with modest debt (~$29.9M; debt/equity ~0.32), provides Savara with durable financial flexibility typical for a development-stage biotech. This backing helps absorb R&D and pre-commercial costs, supports borrowing capacity, and reduces immediate liquidity strain during regulatory execution.

Cash Runway

Holding ~$235.7M in cash and short-term investments gives the company substantive runway to fund ongoing regulatory work, commercial planning and pivotal activities over the next several quarters. For a pre-revenue firm, this liquidity materially lowers near-term financing pressure and supports orderly execution of launch preparations if approval timelines hold.

Regulatory / Pipeline Progress

Filing of the BLA with an assigned PDUFA date, parallel MAAs and pediatric program advancement mark a structural shift toward potential commercialization. These steps, if successful, would validate the clinical strategy, materially change revenue prospects, enable commercial rollout plans already being staffed, and unlock both funding and longer-term growth pathways.

Negative Factors

Pre-Revenue Status

Savara remains a pre-revenue company with no product sales through 2024 and TTM, meaning it must rely on external financing or milestone receipts to fund operations. This structural lack of recurring revenue elevates long-term financing and execution risk, making sustainable profitability contingent on successful regulatory approval and commercial launch.

High Cash Burn

Operating cash flow has deteriorated to roughly -$101M TTM and free cash flow mirrors that shortfall, reflecting accelerating spending to advance development and commercialization readiness. Sustained high burn narrows runway despite cash on hand, limits strategic optionality, and increases the probability of additional financing needs under potentially unfavorable terms.

Funding Contingent on Approval

Material incremental financing is explicitly contingent on product approval: the company cites access to up to $150M in non-dilutive capital only upon MOLBREEVI approval. This creates a binary financing profile where a regulatory delay or denial would force reliance on dilutive or more expensive funding alternatives, raising long-term dilution and cost-of-capital risks.

Savara Business Overview & Revenue Model

Company Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

How the Company Makes Money

null

Savara Financial Statement Overview

Summary

Pre-revenue profile with widening losses (net loss to ~$118.8M TTM) and worsening operating and free-cash-flow burn (~-$101M TTM) materially weigh on quality; partially offset by a relatively supportive balance sheet (equity ~$203.1M TTM) and manageable debt (~$29.9M TTM).

Income Statement

SVRA remains a pre-revenue biotechnology company, with total revenue at $0 in 2021–2024 and in TTM (Trailing-Twelve-Months). Losses have widened materially over time: net loss increased from about $38.2M (2022) to $54.7M (2023) to $95.9M (2024) and $118.8M in TTM (Trailing-Twelve-Months). Operating losses (EBIT) followed the same trajectory, indicating rising cost structure ahead of commercialization. The main positive is that the company is building its pipeline capacity (typical for the industry), but the lack of revenue and accelerating losses keep income statement quality weak.

Balance Sheet

The balance sheet is relatively solid for a development-stage biotech, with meaningful equity backing and moderate leverage. Stockholders’ equity increased from $107.8M (2022) to $140.4M (2023) to $171.4M (2024) and $203.1M in TTM (Trailing-Twelve-Months), supporting financial flexibility. Debt is manageable at ~$29.9M in TTM (Trailing-Twelve-Months), and debt relative to equity is ~0.32 (TTM), which is not excessive. The key weakness is ongoing negative returns on equity (driven by net losses), which signals dilution/financing risk over time if burn continues.

Cash Flow

Cash flow is pressured by consistent and sizable cash burn. Operating cash flow was negative every year, worsening from about -$34.6M (2022) to -$51.1M (2023) to -$89.1M (2024) and -$101.0M in TTM (Trailing-Twelve-Months). Free cash flow is similarly negative, at roughly -$101.1M in TTM (Trailing-Twelve-Months). While free cash flow has occasionally shown positive growth rates (including TTM), the absolute level of cash consumption is high and trending worse versus prior years, increasing reliance on future funding.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-245.00K	-78.03M	-44.26M	-27.88M	-28.99M
EBITDA	-123.46M	-102.27M	-59.13M	-38.01M	-40.50M
Net Income	-118.84M	-95.88M	-54.70M	-38.15M	-43.01M
Balance Sheet
Total Assets	253.44M	212.88M	177.56M	139.78M	176.60M
Cash, Cash Equivalents and Short-Term Investments	235.70M	196.33M	162.32M	125.88M	161.17M
Total Debt	29.91M	26.73M	26.49M	26.14M	25.79M
Total Liabilities	50.30M	41.43M	37.19M	32.00M	32.10M
Stockholders Equity	203.13M	171.45M	140.37M	107.78M	144.50M
Cash Flow
Free Cash Flow	-101.06M	-89.11M	-51.36M	-34.56M	-40.14M
Operating Cash Flow	-101.04M	-89.09M	-51.06M	-34.55M	-40.08M
Investing Cash Flow	-18.44M	-39.94M	-57.12M	52.65M	-69.46M
Financing Cash Flow	137.81M	117.58M	82.78M	87.00K	120.81M

Savara Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.96
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SVRA, the sentiment is Negative. The current price of 4.96 is below the 20-day moving average (MA) of 5.49, below the 50-day MA of 5.61, and above the 200-day MA of 4.23, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 36.90 is Neutral, neither overbought nor oversold. The STOCH value of 15.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SVRA.

Savara Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	73 Outperform	$479.56M	2.10	240.83%	―	79.13%	2798.12%
ANAB	57 Neutral	$1.79B	-101.81	1813.84%	―	196.42%	53.92%
BCAX	56 Neutral	$1.17B	―	-27.17%	―	―	-103.95%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NBTX	48 Neutral	$1.45B	-8.84	76.70%	―	―	―
OLMA	47 Neutral	$1.23B	-13.39	-42.90%	―	―	17.23%
SVRA	46 Neutral	$1.02B	-11.28	-84.01%	―	―	-22.39%

Savara Corporate Events

Savara Signs Long-Term Lease for New Headquarters

On March 10, 2026, Savara Inc. signed a lease with ML7 Yardley Partners, LP for about 10,795 square feet of office space at 19 W. College Avenue, Suite 200, in Yardley, Pennsylvania, with plans to relocate its headquarters there. The lease term begins July 1, 2026, runs through December 1, 2031, and includes an option for a five-year extension.

Savara will pay about $28,337 in monthly base rent in the first year, with roughly 2% annual increases, and total base rent of about $1.78 million over the term after five months of rent abatement. The company will also cover its share of operating expenses, taxes, and utilities and has posted a security deposit of $28,337 under customary commercial lease terms, underscoring a long-term commitment to the new headquarters location.

The most recent analyst rating on (SVRA) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Savara stock, see the SVRA Stock Forecast page.

Savara Enters New Material Definitive Agreement and Obligation

Savara Inc., a Delaware corporation, reported on January 27, 2026, that it had executed a material definitive agreement, as disclosed under Item 1.01 of its filing, and confirmed that the report was duly authorized and signed by Chief Financial and Administrative Officer Dave Lowrance. The filing formally records the company’s entry into this significant agreement, signaling a potentially important development for Savara’s corporate and financial arrangements, though specific operational or strategic implications were not detailed in the disclosure.

The most recent analyst rating on (SVRA) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Savara stock, see the SVRA Stock Forecast page.

Savara Highlights Autoimmune PAP Burden in Updated Presentation

In January 2026, Savara updated its corporate presentation to provide an expanded overview of autoimmune pulmonary alveolar proteinosis (autoimmune PAP), the burden of disease, and the limitations of existing care such as whole lung lavage, an invasive and non‑standardized procedure that does not address the underlying pathophysiology and often must be repeated. The materials underscore significant unmet medical need, including high morbidity, increased healthcare utilization, risk of serious infections, and substantial impact on patients’ daily lives, thereby reinforcing the strategic rationale for Savara’s development of MOLBREEVI and signaling the company’s continued positioning as a specialist player in rare respiratory diseases, with potential implications for future regulatory, clinical, and commercial milestones.

The most recent analyst rating on (SVRA) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Savara stock, see the SVRA Stock Forecast page.